Håkan Johansson to start as BONESUPPORT’s CFO at the end of 2018

Lund, Sweden, 18:00 CET, July 4 2018 – BONESUPPORT an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that are expected to take place at the end of 2018, when Håkan Johansson will replace Björn Westberg as the company’s CFO. Håkan Johansson is an experienced financial executive having most recently served as CFO Tunstall Northern Europe, the UK based healthcare solutions company, and prior to that as CFO at the Swedish toy-maker BRIO.

 “Håkan Johansson has very solid CFO experience and will be a valuable addition to Bonesupport’s leadership team given the exciting journey we have ahead of us. I would like to thank Björn for his support and advice whilst I have served as CEO and his work as a lead contributor to Bonesupport’s successful IPO in June 2017. I wish Björn continued success in his future endeavors”, says Emil Billbäck, BONESUPPORT CEO.


BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.

The Company’s products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT’s total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%.

The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

In addition, BONESUPPORT is looking at opportunities to expand its product offering in the US and has entered into a strategic agreement with Collagen Matrix Inc. to market and distribute products that are complementary to CERAMENT BVF.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com


*CERAMENT G: Not available in the United States, for investigational use only.
CERAMENT V: Not available in the United States.
BONESUPPORT and CERAMENT® are registered trademarks.

For more information contact:


Emil Billbäck, CEO

+46 (0) 46 286 53 70

Citigate Dewe Rogerson

Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews

+44 (0)20 7282 1022

This information is such information as BONESUPPORT HOLDING AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18.00 CET on 4 July 2018.